TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine
Status:
Completed
Trial end date:
2001-05-01
Target enrollment:
Participant gender:
Summary
Primary objective: To compare the pharmacokinetics of rifapentine and 25-desacetyl
rifapentine at three different doses: 600 mg, 900 mg, and 1200 mg.
Secondary objective: To describe any correlation between pharmacokinetic parameters of three
different doses of rifapentine plus a standard dose of isoniazid and the occurrence of
toxicity attributed to anti-tuberculosis treatment.
Phase:
N/A
Details
Lead Sponsor:
Centers for Disease Control and Prevention
Collaborators:
US Department of Veterans Affairs VA Office of Research and Development